Pierluigi Benedetti Panici1, Andrea Giannini2, Margherita Fischetti2, Francesca Lecce2, Violante Di Donato2. 1. Department of Maternal and Child Health and Urological Sciences, Umberto I, "Sapienza" University of Rome, Viale del policlinico 155, 0161, Rome, Italy. pierluigi.benedettipanici@uniroma1.it. 2. Department of Maternal and Child Health and Urological Sciences, Umberto I, "Sapienza" University of Rome, Viale del policlinico 155, 0161, Rome, Italy.
Abstract
PURPOSE OF REVIEW: The aim of this review is to determine, in the light of recent evidences, the role of lymphadenectomy in ovarian cancer. RECENT FINDINGS: The lymphadenectomy in ovarian neoplasms (LION) trial reports no better outcomes and higher complication and mortality rates associated with lymphadenectomy. Even if performed by expert hands, lymphadenectomy has a cost in terms of longer operative time, blood loss, higher rates of transfusions, and intensive unit care. If on the one hand retroperitoneal staging is not correlated to survival benefits both in early and advanced ovarian cancer, on the other hand it is associated with an increased surgery-related morbidity. Surgical treatment of isolated nodal recurrences seems to be feasible and associated with survival benefits.
PURPOSE OF REVIEW: The aim of this review is to determine, in the light of recent evidences, the role of lymphadenectomy in ovarian cancer. RECENT FINDINGS: The lymphadenectomy in ovarian neoplasms (LION) trial reports no better outcomes and higher complication and mortality rates associated with lymphadenectomy. Even if performed by expert hands, lymphadenectomy has a cost in terms of longer operative time, blood loss, higher rates of transfusions, and intensive unit care. If on the one hand retroperitoneal staging is not correlated to survival benefits both in early and advanced ovarian cancer, on the other hand it is associated with an increased surgery-related morbidity. Surgical treatment of isolated nodal recurrences seems to be feasible and associated with survival benefits.
Authors: A Pereira; T Pérez-Medina; J F Magrina; P M Magtibay; A Rodríguez-Tapia; J de León; I Peregrin; L Ortiz-Quintana Journal: Eur J Surg Oncol Date: 2014-04-13 Impact factor: 4.424
Authors: Philipp Harter; Jalid Sehouli; Domenica Lorusso; Alexander Reuss; Ignace Vergote; Christian Marth; Jae-Weon Kim; Francesco Raspagliesi; Björn Lampe; Giovanni Aletti; Werner Meier; David Cibula; Alexander Mustea; Sven Mahner; Ingo B Runnebaum; Barbara Schmalfeldt; Alexander Burges; Rainer Kimmig; Giovanni Scambia; Stefano Greggi; Felix Hilpert; Annette Hasenburg; Peter Hillemanns; Giorgio Giorda; Ingo von Leffern; Carmen Schade-Brittinger; Uwe Wagner; Andreas du Bois Journal: N Engl J Med Date: 2019-02-28 Impact factor: 91.245
Authors: P Harter; K Gnauert; R Hils; T G Lehmann; A Fisseler-Eckhoff; A Traut; A du Bois Journal: Int J Gynecol Cancer Date: 2007-04-12 Impact factor: 3.437
Authors: P Benedetti-Panici; S Greggi; F Maneschi; G Scambia; M Amoroso; C Rabitti; S Mancuso Journal: Gynecol Oncol Date: 1993-11 Impact factor: 5.482
Authors: A Ferrero; A Ditto; G Giorda; A Gadducci; S Greggi; A Daniele; L Fuso; E Panuccio; C Scaffa; F Raspagliesi; P Sismondi; N Biglia Journal: Eur J Surg Oncol Date: 2013-12-14 Impact factor: 4.424
Authors: A Maggioni; P Benedetti Panici; T Dell'Anna; F Landoni; A Lissoni; A Pellegrino; R S Rossi; S Chiari; E Campagnutta; S Greggi; R Angioli; N Manci; M Calcagno; G Scambia; R Fossati; I Floriani; V Torri; R Grassi; C Mangioni Journal: Br J Cancer Date: 2006-08-29 Impact factor: 7.640
Authors: B J Dicken; D F Billmire; B Rich; F K Hazard; M Nuño; M Krailo; N Fallahazad; F Pashankar; F Shaikh; A L Frazier Journal: Gynecol Oncol Date: 2022-06-22 Impact factor: 5.304